Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mpox Neutralizing Antibody Response to LC16m8 Vaccine in Healthy Adults.
Morino E, Mine S, Tomita N, Uemura Y, Shimizu Y, Saito S, Suzuki T, Okumura N, Iwasaki H, Terada J, Ainai A, Sakai Y, Park E, Seki S, Akazawa D, Shimojima M, Shiwa-Sudo N, Virhuez-Mendoza M, Miyauchi K, Moriyama S, Iwata-Yoshikawa N, Harada M, Harada S, Hishiki T, Kotaki R, Matsumura T, Miyamoto S, Kanno T, Isogawa M, Watashi K, Nagata N, Ebihara H, Takahashi Y, Maeda K, Matano T, Wakita T, Suzuki T, Sugiura W, Ohmagari N, Ujiie M. Morino E, et al. Among authors: kotaki r. NEJM Evid. 2024 Mar;3(3):EVIDoa2300290. doi: 10.1056/EVIDoa2300290. Epub 2024 Feb 27. NEJM Evid. 2024. PMID: 38411447
A broad antibody class engages the influenza virus hemagglutinin head at its stem interface.
Simmons HC, Finney J, Kotaki R, Adachi Y, Moseman AP, Watanabe A, Song S, Robinson-McCarthy LR, Sage VL, Kuraoka M, Moseman EA, Kelsoe G, Takahashi Y, McCarthy KR. Simmons HC, et al. Among authors: kotaki r. bioRxiv [Preprint]. 2023 Dec 14:2023.12.13.571543. doi: 10.1101/2023.12.13.571543. bioRxiv. 2023. PMID: 38168412 Free PMC article. Preprint.
Protective human antibodies against a conserved epitope in pre- and postfusion influenza hemagglutinin.
Finney J, Moseman AP, Kong S, Watanabe A, Song S, Walsh RM Jr, Kuraoka M, Kotaki R, Moseman EA, McCarthy KR, Liao D, Liang X, Nie X, Lavidor O, Abbott R, Harrison SC, Kelsoe G. Finney J, et al. Among authors: kotaki r. Proc Natl Acad Sci U S A. 2024 Jan 2;121(1):e2316964120. doi: 10.1073/pnas.2316964120. Epub 2023 Dec 26. Proc Natl Acad Sci U S A. 2024. PMID: 38147556 Free PMC article.
Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants.
Moriyama S, Anraku Y, Taminishi S, Adachi Y, Kuroda D, Kita S, Higuchi Y, Kirita Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y. Moriyama S, et al. Among authors: kotaki r. Nat Commun. 2023 Jul 14;14(1):4198. doi: 10.1038/s41467-023-39890-8. Nat Commun. 2023. PMID: 37452031 Free PMC article.
CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes.
Onodera T, Sax N, Sato T, Adachi Y, Kotaki R, Inoue T, Shinnakasu R, Nakagawa T, Fukushi S, Terooatea T, Yoshikawa M, Tonouchi K, Nagakura T, Moriyama S, Matsumura T, Isogawa M, Terahara K, Takano T, Sun L, Nishiyama A, Omoto S, Shinkai M, Kurosaki T, Yamashita K, Takahashi Y. Onodera T, et al. Among authors: kotaki r. Sci Adv. 2023 Jun 16;9(24):eadf0661. doi: 10.1126/sciadv.adf0661. Epub 2023 Jun 14. Sci Adv. 2023. PMID: 37315144 Free PMC article.
Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain.
Takano T, Sato T, Kotaki R, Moriyama S, Fukushi S, Shinoda M, Kabasawa K, Shimada N, Kousaka M, Adachi Y, Onodera T, Terahara K, Isogawa M, Matsumura T, Shinkai M, Takahashi Y. Takano T, et al. Among authors: kotaki r. Nat Commun. 2023 Mar 15;14(1):1451. doi: 10.1038/s41467-023-37128-1. Nat Commun. 2023. PMID: 36922492 Free PMC article.
Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization.
Miyamoto S, Arashiro T, Ueno A, Kanno T, Saito S, Katano H, Iida S, Ainai A, Ozono S, Hemmi T, Hirata Y, Moriyama S, Kotaki R, Kinoshita H, Yamada S, Shinkai M, Fukushi S, Takahashi Y, Suzuki T. Miyamoto S, et al. Among authors: kotaki r. iScience. 2023 Feb 17;26(2):105969. doi: 10.1016/j.isci.2023.105969. Epub 2023 Jan 13. iScience. 2023. PMID: 36687316 Free PMC article.
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Miyamoto S, Arashiro T, Adachi Y, Moriyama S, Kinoshita H, Kanno T, Saito S, Katano H, Iida S, Ainai A, Kotaki R, Yamada S, Kuroda Y, Yamamoto T, Ishijima K, Park ES, Inoue Y, Kaku Y, Tobiume M, Iwata-Yoshikawa N, Shiwa-Sudo N, Tokunaga K, Ozono S, Hemmi T, Ueno A, Kishida N, Watanabe S, Nojima K, Seki Y, Mizukami T, Hasegawa H, Ebihara H, Maeda K, Fukushi S, Takahashi Y, Suzuki T. Miyamoto S, et al. Among authors: kotaki r. Med. 2022 Apr 8;3(4):249-261.e4. doi: 10.1016/j.medj.2022.02.006. Epub 2022 Mar 4. Med. 2022. PMID: 35261995 Free PMC article.
22 results